Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma in vivo-Reference-Cited by-同舟云学术

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma in vivo

Published:2016-03-26 Issue:17 Volume:7 Page:24752-24765
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Xu Wen¹²,Bi Yanyu²,Kong Juan²,Zhang Jiqin²,Wang Biao²,Li Kesang²,Tian Mi²,Pan Xiaorong²,Shi Bizhi²,Gu Jianren²,Jiang Hua²,Kong Xianming³,Li Zonghai²

Affiliation:

1. Medical School of Fudan University, Shanghai, China

2. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

3. Renji Hospital, Medical School of Shanghai Jiaotong University, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities;International Journal of Molecular Sciences;2024-02-15

2. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?;Cancers;2021-11-18

3. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities;Nature Communications;2020-06-10

4. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development;Expert Opinion on Investigational Drugs;2020-06-04

5. Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys;Molecular Therapy;2018-06